Akeso and Summit Therapeutics reported updated Phase 3 data for ivonescimab, arguing the updated dataset clears the trial’s overall survival threshold bar in certain lung cancer patients. The companies framed the result as a step back toward the overall survival confidence investors seek after earlier interim readouts shook sentiment. Full confirmatory evidence is still expected to rely on forthcoming global data.